Podcasts about Bruton

Human settlement in England

  • 252PODCASTS
  • 558EPISODES
  • 46mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • Jan 7, 2023LATEST
Bruton

POPULARITY

20152016201720182019202020212022


Best podcasts about Bruton

Show all podcasts related to bruton

Latest podcast episodes about Bruton

Authors on the Air Global Radio Network
OutWithDan EP 29 - Keith Bruton - THE LEMON MAN

Authors on the Air Global Radio Network

Play Episode Listen Later Jan 7, 2023 15:51


Season 2 opens with one of the most delightful books that I have read in a long time. Keith Bruton has crafted a fun (and sometimes funny) tale of a Hitman with OCD. After a very clean and direct "hit" Patrick discovers something completely unexpected at the scene: a baby. Unable to leave the crying, hungry and dirty Little Bugger behind, the baby becomes a new addition to Patrick's everyday life. What could possible go wrong? Or right?

Authors on the Air Global Radio Network
OutWithDan EP 29 - Keith Bruton - THE LEMON MAN

Authors on the Air Global Radio Network

Play Episode Listen Later Jan 7, 2023 15:51


Season 2 opens with one of the most delightful books that I have read in a long time. Keith Bruton has crafted a fun (and sometimes funny) tale of a Hitman with OCD. After a very clean and direct "hit" Patrick discovers something completely unexpected at the scene: a baby. Unable to leave the crying, hungry and dirty Little Bugger behind, the baby becomes a new addition to Patrick's everyday life. What could possible go wrong? Or right?

Keeping Current
Spotlight on Chronic Lymphocytic Leukemia: Exploring the Continued Evolution of Bruton Tyrosine Kinase Inhibitors for Our Patients

Keeping Current

Play Episode Listen Later Jan 4, 2023 28:56


Did you know there are 3 Bruton tyrosine kinase (BTK) inhibitors approved to treat chronic lymphocytic leukemia (CLL) in Europe? Credit available for this activity expires: 1/4/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/986280?ecd=bdc_podcast_libsyn_mscpedu

The Be More Today Show
EP 112: "Reset. Relearn. Reinforce.” featuring Super Bowl Champ and PT Dr. David Bruton, Jr.

The Be More Today Show

Play Episode Listen Later Jan 2, 2023 53:51


Dr. David Bruton Jr. is a former athlete turned physical therapist, who graduated from the University of Colorado in 2021.  David is the founder of Bruton's Books, a childhood literacy foundation, and Between the Lines Physical Therapy.  David was a former safety for the Denver Broncos for 7 years, and 1 year with the Washington Football Team.  During his tenure with the Broncos he was a captain for 3 years and won Super Bowl 50. After retirement, David followed his heart towards a lifelong passion for the profession of physical therapy  and having a collaborative relationship with patients to help them return to their prior level of function and beyond.  David's passion for providing great healthcare was ignited as a youth playing sports, where his PT's throughout every stage of his playing career, helped him achieve and return to a high level of play.  That love was continuously reinforced throughout physical therapists throughout college and professionally.  Dr. Bruton Jr. has been dedicated in educating himself in order to provide the best patient care through multiple certifications and seeking further learning opportunities. He is also an active member of the Scholarship Endowment Board at CU and is Co-president of the CU PT Alumni Association. Aside from his love of PT, David loves his wife and kids, cycling, working out, board games, snowboarding, and giving back to the community. For more information about Between the Lines PT visit https://betweenthelinespt.com/ --- Send in a voice message: https://anchor.fm/bemoretoday/message Support this podcast: https://anchor.fm/bemoretoday/support

Minor League Sports Report
Muskies Matters with Lakeland Head Coach Colin Bruton: Season 6, Episode 13

Minor League Sports Report

Play Episode Listen Later Dec 24, 2022 28:53


In this week's episode of Muskies Matters with Lakeland University Head Football Coach Colin Bruton, the Coach Discusses the preparation for quarterback Robby Michael for next season, he gives us his thoughts on Tom Brady and his future, and we learn if the Coach is one of those guys who excessively decorates his home during Christmas time. Plus, the Coach gives us his words of wisdom for this Christmas. This and much more. Enjoy!

Sports Show with Rowey & Bicks
INTERVIEW: C.J. Bruton - 20 December 2022

Sports Show with Rowey & Bicks

Play Episode Listen Later Dec 20, 2022 9:16


See omnystudio.com/listener for privacy information.

Sports Show with Rowey & Bicks
FIVEaa Summer Sports Show - 20 December 2022

Sports Show with Rowey & Bicks

Play Episode Listen Later Dec 20, 2022 94:40


C.J. Bruton, Heath Shelmerdine, Heath Younie, Brayden Hein, Chris AdamsonSee omnystudio.com/listener for privacy information.

Sports Show with Rowey & Bicks
INTERVIEW: C.J. Bruton - 16 December 2022

Sports Show with Rowey & Bicks

Play Episode Listen Later Dec 16, 2022 7:16


See omnystudio.com/listener for privacy information.

Sports Show with Rowey & Bicks
Rowey & Timmy G Podcast - 16 December 2022

Sports Show with Rowey & Bicks

Play Episode Listen Later Dec 16, 2022 91:49


C.J. Bruton, Charlie Dixon, Brodie Smith, Robbie SlaterSee omnystudio.com/listener for privacy information.

Sports Show with Rowey & Bicks
Rowey & Timmy G Podcast - 1 December 2022

Sports Show with Rowey & Bicks

Play Episode Listen Later Dec 1, 2022 91:13


Robbie Slater. Daniel Cherny, C.J. Bruton, Giancarlo Fisichella, Daniel GarbSee omnystudio.com/listener for privacy information.

Sports Show with Rowey & Bicks
INTERVIEW: C.J. Bruton - 1 December 2022

Sports Show with Rowey & Bicks

Play Episode Listen Later Dec 1, 2022 6:11


See omnystudio.com/listener for privacy information.

VJHemOnc Podcast
Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more

VJHemOnc Podcast

Play Episode Listen Later Nov 25, 2022 11:35


The treatment landscape of chronic lymphocytic leukemia (CLL) has transformed over the years with the increased use of Bruton's tyrosine... The post Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more appeared first on VJHemOnc.

Sports Show with Rowey & Bicks
Rowey & Timmy G Podcast - Variety Radiothon - 25 November 2022

Sports Show with Rowey & Bicks

Play Episode Listen Later Nov 25, 2022 72:45


C.J. Bruton, Mark Bickley, Tegan McPharlin See omnystudio.com/listener for privacy information.

Sports Show with Rowey & Bicks
INTERVIEW: C.J. Bruton - 25 November 2022

Sports Show with Rowey & Bicks

Play Episode Listen Later Nov 25, 2022 5:12


See omnystudio.com/listener for privacy information.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Jiwon Oh, MD, PhD, FRCPC - Moving Toward the Future in MS Management: What's the Latest on BTK Inhibition?

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Nov 22, 2022 32:36


Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.

PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
Jiwon Oh, MD, PhD, FRCPC - Moving Toward the Future in MS Management: What's the Latest on BTK Inhibition?

PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 22, 2022 32:34


Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Jiwon Oh, MD, PhD, FRCPC - Moving Toward the Future in MS Management: What's the Latest on BTK Inhibition?

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 22, 2022 32:34


Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Jiwon Oh, MD, PhD, FRCPC - Moving Toward the Future in MS Management: What's the Latest on BTK Inhibition?

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 22, 2022 32:34


Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Jiwon Oh, MD, PhD, FRCPC - Moving Toward the Future in MS Management: What's the Latest on BTK Inhibition?

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Nov 22, 2022 32:36


Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Jiwon Oh, MD, PhD, FRCPC - Moving Toward the Future in MS Management: What's the Latest on BTK Inhibition?

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Nov 22, 2022 32:36


Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Jiwon Oh, MD, PhD, FRCPC - Moving Toward the Future in MS Management: What's the Latest on BTK Inhibition?

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 22, 2022 32:34


Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.

PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
Jiwon Oh, MD, PhD, FRCPC - Moving Toward the Future in MS Management: What's the Latest on BTK Inhibition?

PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast

Play Episode Listen Later Nov 22, 2022 32:36


Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.

Minor League Sports Report
Muskies Matters with Lakeland Head Coach Colin Bruton: Season 6, Episode 12

Minor League Sports Report

Play Episode Listen Later Nov 19, 2022 24:32


In this week's episode of Muskies Matters with Lakeland University Head Football Coach Colin Bruton, the Coach discusses the season ending victory over Rockford, he talks about the bright future ahead at Lakeland, and he gives us his top five dishes that should not be eaten at Thanksgiving. Plus, the Coach gives us his words of wisdom for the week. This and much more. Enjoy!

Blood Podcast
Transplant in adult Ph+ ALL, acalabrutinib and ventricular arrythmias, and antibody prevention of fetal/neonatal alloimmune thrombocytopenia

Blood Podcast

Play Episode Listen Later Nov 17, 2022 18:45


In this week's episode we discuss the role of allogeneic transplant in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. In a retrospective study, transplant provided no survival benefit in patients with rapid and deep responses to induction therapy that included BCR-ABL1 inhibitors. Up next, we discuss the evidence for an increased risk of ventricular arrythmias with use of acalabrutinib, which has emerged as a class effect of Bruton tyrosine kinase inhibitors. Lastly, we examine a novel, alloantigen-specific model to test the efficacy of a prophylactic treatment strategy for preventing fetal/neonatal alloimmune thrombocytopenia.

Minor League Sports Report
Muskies Matters with Lakeland Head Coach Colin Bruton: Season 6, Episode 11

Minor League Sports Report

Play Episode Listen Later Nov 11, 2022 27:59


In this week's episode of Muskies Matters with Lakeland University Head Football Coach Colin Bruton, the Coach discusses the loss to Aurora and the final game against Rockford, he talks a little sports with us, and we learn how he celebrated the clocks falling back an hour. Plus, the Coach shares some words of wisdom. This and much more. Enjoy!

Sports Show with Rowey & Bicks
INTERVIEW: CJ Bruton - 10 November 2022

Sports Show with Rowey & Bicks

Play Episode Listen Later Nov 10, 2022 10:36


See omnystudio.com/listener for privacy information.

Keeping Current
Solving the Puzzles for B-Cell Malignancies: Navigating the Place of BTK Inhibitors Today and Tomorrow

Keeping Current

Play Episode Listen Later Nov 8, 2022 92:13


Did you know that using Bruton tyrosine kinase (BTK) inhibitors can lead to chemotherapy-free regimens for treating certain B-cell malignancies? Credit available for this activity expires: 11/7/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/983523?src=mkm_podcast_addon_983523

Minor League Sports Report
Muskies Matters with Lakeland Head Coach Colin Bruton: Season 6, Episode 10

Minor League Sports Report

Play Episode Listen Later Nov 4, 2022 26:57


In this week's episode of Muskies Matters with Lakeland University Head Football Coach Colin Bruton, the Coach discusses the big victory over Eureka and his keys against Aurora, he discusses the prospects for the future for the Muskies, and tells us when is the appropriate time for Christmas to officially begin. Plus, he shares some words of wisdom. This and much more. Enjoy!

Meet The Elite Podcast
5494 Nelson Bruton-11 02 22-Marketing Industrial Manufacturing-James

Meet The Elite Podcast

Play Episode Listen Later Nov 3, 2022 4:19


Minor League Sports Report
Muskies Matters with Lakeland Head Coach Colin Bruton: Season 6, Episode 9

Minor League Sports Report

Play Episode Listen Later Oct 28, 2022 25:37


In this week's episode of Muskies Matters with Lakeland University Head Football Coach Colin Bruton, the Coach discusses the tough performance and his keys against Eureka this week, he shares his thoughts on his beloved Bears and how happy he is to see the Packers failing, and the Coach tells us how he comes up with his inspirational thought. Plus, he shares some words of wisdom. This and much more. Enjoy!

Sports Show with Rowey & Bicks
INTERVIEW: C.J. Bruton - 27 October 2022

Sports Show with Rowey & Bicks

Play Episode Listen Later Oct 27, 2022 17:33


See omnystudio.com/listener for privacy information.

The Dale Jr. Download - Dirty Mo Media
405 - Marcus Smith - NEW Details About The All-Star Race at North Wilkesboro

The Dale Jr. Download - Dirty Mo Media

Play Episode Listen Later Oct 25, 2022 110:03 Very Popular


Back in September, the stock car racing world was turned upside down when the announcement was made that the 2023 NASCAR All-Star race would be held at the recently revived North Wilkesboro Speedway. On this week's episode of The Dale Jr. Download, Dale Earnhardt Jr. and co-host Mike Davis sit down with the man who helped make the decision, CEO and President of Speedway Motorsports Incorporated Marcus Smith. Devotees of The Download will recognize that this marks Smith's fifth appearance on the show, and his yearly check-in usually provides great insight into some of the upcoming projects in the NASCAR world. Much has changed since Marcus' last visit in May 2021, most notably the passing of his father Bruton, who was a major contributor to the racing world and founder of SMI. Marcus reflects on the difficult process of coming to terms with his father's declining health but is thankful that he lived a long life of 95 years. He also explains how his father got his start in car sales by running a used car lot on his mother's front lawn. Though he was eventually shut down by city officials, his knack for the industry eventually led to him forming Sonic Automotive, the fifth-largest automotive retailer in the country. The interview addresses the rumors surrounding the reconfiguration of Texas Motor Speedway. Dale and Marcus unpack the September Cup race held at the Fort Worth-based track and discuss what can be done to help boost attendance while keeping competitors and teams happy. Marcus explains that with the current grandstand set-up, there are limited changes that can be made to the track's actual configuration. However, alterations can be made to the speedway's profile, much like the recent reshaping of Atlanta Motor Speedway. In fact, with the help of iRacing, they've been able to model potential changes and test through simulation to see what effect they'd have on the racing product. The process was essential to the work done in Atlanta, and the results found in the trial runs were comparable to the actual Cup races held this season. In addition to the changes made to the racing surface at Atlanta, there have been talks of bringing a casino resort to the grounds in an effort to build up the area similar to that of Kansas Speedway. Marcus explains that in order for the plans to go through, there needs to be an amendment made to the Georgia state constitution that would allow for sports gambling, and encourages listeners and supporters of the speedway to be vocal to their local representatives. Another huge topic of discussion was the status of the Nashville Fairgrounds project. Those following along will remember that Dale and Marcus have been huge proponents in bringing NASCAR Cup racing back to the famed oval. Marcus makes clear that while they have been seemingly stuck in place for a while, progress is being made on the initiative.  A glimmer of hope in bringing relics of NASCAR's past back to life has been the return of North Wilkesboro Speedway. Dale and Marcus reflect on the huge success of the recent CARS Late Model Stock Car race at the track and fill listeners in on the changes and upgrades being made to the facility in anticipation of next year's All-Star event. Aside from additional seating being brought in, improvements are being made to the facilities, scoring system, retaining walls, and traffic flow.  The conversation also touches on NASCAR's ongoing television contract discussions and what it means for the tracks and the Race Team Alliance. Tune in for insight from one of the great minds and innovators in the motorsports industry regarding what it takes to run a speedway and what all parties can do to help the sport grow as a whole.  Check out northwilkesborospeedway.com for updates/details. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Minor League Sports Report
Muskies Matters with Lakeland Head Coach Colin Bruton: Season 6, Episode 8

Minor League Sports Report

Play Episode Listen Later Oct 21, 2022 25:29


In this week's episode of Muskies Matters with Lakeland University Head Football Coach Colin Bruton, the Coach discusses earning the first victory of the season and what to expect against Concordia-Wisconsin, he talks about the struggle of the special teams, and we learn how the Coach stays so thin. Plus, he shares some words of wisdom. This and much more. Enjoy!

Minor League Sports Report
Muskies Matters with Lakeland Head Coach Colin Bruton: Season 6, Episode 7

Minor League Sports Report

Play Episode Listen Later Oct 14, 2022 26:17


In this week's episode of Muskies Matters with Lakeland University Head Football Coach Colin Bruton, the Coach discusses the disappointing loss to Benedictine and the excitement of homecoming week, he talks about hazing and whether that should be allowed in colleges, and we learn what is something the coach can do that maybe no one else he knows can. Plus, the Coach shares some words of wisdom with us.. This and much more. Enjoy!

Sports Show with Rowey & Bicks
Rowey & Timmy G Podcast - 12 October 2022

Sports Show with Rowey & Bicks

Play Episode Listen Later Oct 12, 2022 77:48


Ben Williams, C.J. Bruton, Jade Sheedy, Tim Weatherald, Billy Frampton, Drew JonesSee omnystudio.com/listener for privacy information.

Sports Show with Rowey & Bicks
INTERVIEW: C.J. Bruton - 12 October 2022

Sports Show with Rowey & Bicks

Play Episode Listen Later Oct 12, 2022 8:04


See omnystudio.com/listener for privacy information.

Minor League Sports Report
Muskies Matters with Lakeland Head Coach Colin Bruton: Season 6, Episode 6

Minor League Sports Report

Play Episode Listen Later Oct 7, 2022 26:16


In this week's episode of Muskies Matters with Lakeland University Head Football Coach Colin Bruton, the Coach discusses the team coming out of the bye week and what he expects against Benedictine this week, he tells us who he thinks is better between Georgia and Alabama, and shares his thoughts on the biggest blunders in military history. Plus, Coach Bruton share some words of wisdom. This and much more. Enjoy!

RTÉ - Your Politics
Price caps may worsen crisis - Bruton

RTÉ - Your Politics

Play Episode Listen Later Sep 22, 2022 29:32


It would be "very naive" to hope for a quick fix to the current crisis, Fine Gael's Richard Bruton warns, and we "have to keep something in the tank". He joins Paul Cunningham, Mary Regan and Micheál Lehane to caution against price caps - which could be exploited by private interests. Retrofitting and pensions are also on the Your Politics agenda.

Cancer.Net Podcasts
2022 Research Round Up: Lung Cancer, Lymphoma, and Childhood Cancers

Cancer.Net Podcasts

Play Episode Listen Later Sep 15, 2022 30:09


ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. In the Research Round Up series, ASCO experts and members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today's episode, our guests will discuss new research in lung cancer, lymphoma, and childhood cancer that was presented at the 2022 ASCO Annual Meeting, held June 3-7 in Chicago, Illinois. First, Dr. Charu Aggarwal will discuss 3 studies looking at treatment options for people with non-small cell lung cancer. Dr. Aggarwal is the Leslye Heisler Associate Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania's Perelman School of Medicine in Philadelphia, Pennsylvania. She is also the Cancer.Net Associate Editor for Lung Cancer. You can view Dr. Aggarwal's disclosures at Cancer.Net. Dr. Aggarwal: Hello and welcome to this Cancer.Net podcast. I'm bringing you updates from the Annual Meeting of the American Society of Clinical Oncology, held in Chicago in 2022. I'm Dr. Charu Aggarwal. I'm the Leslye Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania's Abramson Cancer Center. I will be discussing updates on 3 studies today that offer insights and new advances in the management of patients with non-small cell lung cancer. I don't have any direct relationship with any of these companies or studies, and you can view a list of my disclosures on the Cancer.Net website. First off, I would like to talk a little bit about advances in the management of patients with EGFR exon 20 mutations. We know that a lot of advances have been made in the management of patients with non-small cell lung cancer, and much of that has been attributed to the fact that we are now able to deliver targeted therapy for a subset of patients. EGFR mutations form one such subset where we have a lot of oral drugs that are available, and we can offer these that improve survival, and patients can avoid chemotherapy, immunotherapy, and other IV infusional therapies. Within the subset of EGFR mutations lies this unique subset of EGFR exon 20 insertion mutations, which have been historically harder to target with currently available EGFR inhibitors. And over the last 5 years, we have seen tremendous growth of opportunities, targets, and new drugs for this subset of patients. The mutations in this subset forms about 2% to 5% of all non-small cell lung cancers. But now we have 2 FDA-approved drugs in this space, one being intravenously administered, amivantamab, and another that is orally available, mobocertinib. We covered this in a podcast as well as a blog, so please check those out on our Cancer.Net website. But building upon that progress, there is now another drug that was reported at ASCO. This drug is called CLN-081. And we saw preliminary activity in a phase 1 and 2 study of this molecule or this drug in patients with EGFR exon 20 insertion mutations. It's an orally available drug. The top line data is that it is safe, it is effective, it was tested in different doses. It was tested at less than 65 milligrams, 100 milligrams, and 150 milligrams, again, as I mentioned, administered orally, and we saw responses and patients that had previously received other therapies and may have progressed on other therapies. And what we found was that this drug also tends to have activity against brain metastases, which I think is this huge unmet need in the management of such patients. So I think more to come, but again, I think offers us an insight into what may be in the future, an attractive drug for our patients with EGFR exon 20 insertion mutations. So stay tuned, more on that in the future. Shifting gears, I would like to now talk about one of the common mutations. So we talked about EGFR exon 20, which is about only 2% to 5%, but the largest subset of mutations in non-small cell lung cancer really revolves around KRAS mutations, and these form about 30% to 35% of all mutations in non-squamous, non-small cell lung cancer. And amongst this group there is another subset which is KRAS G12C non-small cell lung cancer, that forms about 13% of all lung cancers. We have 1 approved drug already in this space by the name of sotorasib that is FDA approved for the management of patients with this particular mutation after having received 1 prior therapy, be it chemo-immunotherapy or immunotherapy. At this year's ASCO meeting, we heard data from a study called KRYSTAL-1, which looked at the activity and safety of another molecule called adagrasib, which is an orally available drug targeting KRAS G12C, again, in a similar population of patients with advanced and metastatic non-small cell lung cancer harboring a mutation. We found that this drug is again effective, the overall response rate was about 43%, the majority of the patients had stabilization of disease, about 80%, and many patients were able to remain on treatment with stabilization of disease. We found that this drug does have side effects and adverse events and most commonly of this were diarrhea, nausea, vomiting, and fatigue. Many patients did require dose reductions, but the activity of the drug remained despite dose reductions. Now, what would be the advantage of this drug against the currently available sotorasib? In another smaller study reported at ASCO, there seemed to be activity in the brain, including intracranial penetration with the use of this molecule, adagrasib, which has not been demonstrated before with other KRAS G12C inhibitors, so I think that makes it a potentially attractive option. Again, I will say that the report of this intracranial activity was in a very small subgroup of patients, so I think needs to be further corroborated in a larger study. Shifting gears again and talking about our last study, so I would like to highlight what do we do if, in case, patients don't have a targetable mutation. I want to highlight that we do have a lot of available options, and we are continuing to improve upon available options. The way we treat such patients is by using immunotherapy, either alone or in combination with chemotherapy. But what do we do after this treatment stops working? Researchers from the Southwestern Oncology Group, or SWOG, launched a massive national effort called Lung-MAP, which is basically a clinical trial that evaluates several different strategies all at once, either for patients with targetable mutations or for patients without a targetable alteration. And they reported results from a study that evaluated the combination of pembrolizumab with ramucirumab in patients that may have progressed after frontline immunotherapy. Now, pembrolizumab is immunotherapy, so the concept was, can we continue immunotherapy beyond progression and perhaps get some synergistic activity by using ramucirumab, which is a drug that prevents blood vessels from forming in the tumor itself. It's an anti-angiogenic agent, meaning that it is a targeted molecule that prevents blood vessel formation and promotes tumor death. What they found was that patients that received pembrolizumab and ramucirumab were more likely to live longer, so overall survival was longer for patients with this combination compared to a physician investigator discretion choice, such as chemotherapy in combination with ramucirumab or other chemotherapies that are otherwise used in the second line setting. And interestingly, we did not find a significant improvement in shrinkage with this combination of pembrolizumab and ramucirumab or a significant reduction in the time of progression-- or, sorry, prolongation of the time of progression of disease. But the overall survival findings are interesting, and I think that's why we are including them in this podcast because that's one of the approaches that is leading to an improvement in survival and improvement in outcomes. I will point out that this is a phase 2 study. These results would need to be validated in a large prospective phase 3 trial so that we can account for certain confounding factors that may have led to these results. Having said that, I think there's a tremendous excitement, there's tremendous excitement in this field. I gave you examples of, or highlighted, 3 studies: one in patients with EGFR exon 20 insertion mutations, another in KRAS G12C mutations, and the third in patients who may have already received either immunotherapy or chemoimmunotherapy. We will continue to update our Cancer.Net website with updates as they come through, new advances, new studies, so thanks for following, thanks for listening, and more to come. Stay tuned. Thank you. ASCO: Thank you, Dr. Aggarwal. Next, Dr. Christopher Flowers will discuss new research in treating people with different subtypes of lymphoma, including mantle cell lymphoma and diffuse large B-cell lymphoma. Dr. Flowers is the Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center and was appointed Division Head ad interim of Cancer Medicine in August 2020. He is also the 2022 Cancer.Net Associate Editor for Lymphoma.   You can view Dr. Flowers' disclosures at Cancer.Net. Dr. Flowers: Hello and welcome to this podcast that is a review of late breaking abstracts from the ASCO Meeting and recent updates in lymphoma. I'm Dr. Christopher Flowers, professor and chair of the Department of Lymphoma and Myeloma and Interim Division Head for Cancer Medicine at The University of Texas MD Anderson. And it's my great pleasure to discuss with you some of these late breaking abstracts. I do have some disclosures that are related to the content that I will present from this year's ASCO Meeting and recent studies in lymphomas. Those are available at Cancer.Net. Those relate to my role as a consultant for the development of clinical trials in lymphomas and research funding that MD Anderson has received from companies related to my role in clinical trials in lymphoma and clinical trials across cancers. So, the ASCO Meeting had a host of new information that was presented. Some of that information centers around key clinical trials. One that was a pivotal clinical trial, the SHINE clinical trial, looked at patients with mantle cell lymphoma, a rarer lymphoma subtype, that looked at the combination of bendamustine and rituximab, a standard chemoimmunotherapy combination, compared to that same chemoimmunotherapy combination, bendamustine, rituximab, plus the Bruton's tyrosine kinase inhibitor ibrutinib. Ibrutinib, as some of you may know, is a kind of therapy that is typically used in the relapse setting for patients with mantle cell lymphoma when they have their disease come back. And the SHINE clinical trial was looking at adding it to frontline therapy. What this randomized, controlled trial in the phase 3 setting found was that patients who received the combination of bendamustine, rituximab, plus ibrutinib had improvement in their progression-free survival, meaning that the time that it took for their disease to come back or them to have deaths related to the lymphoma was longer for patients who received this combination. About 2.3 years longer than the group that received bendamustine, rituximab, plus placebo. And in total, that led to a median progression-free survival of 6.7 years. That study has now been published in the New England Journal of Medicine and was led by my colleague Dr. Michael Wong from MD Anderson. Dr. Wong also led another study that was presented at the ASCO Meeting looking at CAR T-cell therapy for patients with mantle cell lymphoma. That study has now been published in the Journal of Clinical Oncology, and it looks at brexucabtagene autoleucel, a kind of CAR T-cell therapy, where that-- the CAR T-cell therapy was successfully manufactured for 71 of the 74 patients in the trial. 68 of those patients received an infusion and the median progression-free survival, so the average amount of time that it took for patients to have progression of their disease, was about 25 months. And so a marked benefit for those patients who were receiving CAR T-cell therapy when their mantle cell lymphoma came back. There also were major breaking abstracts at the ASCO Meeting in the area of diffuse large B-cell lymphoma. As many of you may know, diffuse large B-cell lymphoma is the most common type of lymphoma that occurs in the United States. And there was a breaking trial that was presented in December at the American Society of Hematology Meeting describing polatuzumab, a CD79b antibody drug conjugate, as a new drug in the substitution of frontline therapy for patients with diffuse large B-cell lymphoma in combinations with rituximab, cyclophosphamide, adriamycin, and prednisone, or the pola-R-CHP arm, that compared favorably to rituximab and CHOP chemotherapy, which has been the standard of care for patients with diffuse large B-cell lymphoma. And that trial showed an improvement in progression-free survival. At this year's ASCO Meeting, Franck Morschhauser presented results from looking at subsets of that patient population. Those patients who had BCL2 by immunohistochemistry that was positive or MYC expression by immunohistochemistry that was positive, or both of those, what we call double-expressor lymphomas, those who have poorer risk than standard groups. And those double-expressor lymphomas, treated with pola-R-CHP, had improvement in progression-free survival compared to R-CHOP with a hazard ratio of 0.64 in that group. We also saw in a multitude of analysis that that supported the benefit of pola-R-CHP in patients with both BCL2-positive and MYC-positive diffuse large B-cell lymphoma. Another area that has been very hot in diffuse large B-cell lymphoma clinical trials is the role of bispecific antibodies. Bispecific antibodies are antibodies that bind both to CD20, a marker on the diffuse large B-cell or the lymphoma cells, and to the marker CD3, which is a marker on T-cells which brings the normal T-cells of the immune system in close proximity to the lymphoma cells and then leads to immune-directed killing of lymphoma cells. The agent glofitamab is an agent that was presented by Michael Dickinson at this year's ASCO Meeting in an abstract. And in this study, 107 patients who received more than 1 dose of steady treatment went on to have complete responses in about 35% of patients. And this showed that glofitamab induced durable complete responses and had a very favorable safety profile in patients with relapsed and refractory diffuse large B-cell lymphoma. And in this trial, they compared that also for patients who had prior exposure to CAR T-cells and showed that responses were also good in those patients. Another set of studies has also looked at bispecific antibodies and a whole host of other areas with multitude of other agents. Another study that was presented at this year's ASCO Meeting explored the use of bispecific antibodies in the frontline setting in combination with the R-CHOP regimen that I just discussed. In that study, Lorenzo Falchi presented results of the subcutaneous bispecific antibody epcoritamab in combination with R-CHOP. This was a relatively small study of 33 patients that showed that the combination of epcoritamab plus R-CHOP was something that was safe and tolerable. There were no new treatment emergent adverse events that led to discontinuation of epcoritamab in the study. And there are some adverse events that are of special interest that we see with the bispecific antibodies, and those include the kind of immune-mediated adverse events that we can also see with CAR T-cells, like cytokine release syndrome, or CRS, or neurologic toxicities that we can see there that are also called ICANS. What we've seen in this trial, that about 42% of patients had some form of cytokine release syndrome, but that most severe form of cytokine release syndrome, those that were greater than grade 3 in severity, was only in 3% of patients. And likewise, the neurologic toxicities, or ICANS, that were grade 2 was in only 3% of patients. Relatively few patients completed all therapy by the time that this was presented. Only 10 patients had completed 6 cycles of therapy, but that showed an overall response rate that was quite high in that patient population. There were a whole host of other trials that were presented at this year's ASCO Meeting, and those portend improved kinds of outcomes on the horizon for patients with lymphomas across the spectrum. And I think it's an exciting time moving forward for clinical trials in lymphoma and hopefully, to see new therapies that emerge for the management of this disease. One of those new therapies that happened outside of the ASCO Meeting was the recent FDA approval of CAR T-cell therapy in the relapse setting for follicular lymphoma. And this was based on the ELARA clinical trial. And I think the future is quite bright for therapies and for patients with lymphomas broadly. ASCO: Thank you, Dr. Flowers. Finally, Dr. Daniel Mulrooney will discuss new research in childhood cancers, including a study comparing treatment options for Ewing sarcoma, and several studies on neuroblastoma. Dr. Mulrooney is an Associate Member in the Division of Cancer Survivorship at St. Jude Children's Research Hospital. He is also the Cancer.Net Associate Editor for Pediatric Cancers. You can view Dr. Mulrooney's disclosures at Cancer.Net. Dr. Mulrooney: My name is Dr. Dan Mulrooney from St. Jude Children's Research Hospital. I'm the Deputy Director of the After Completion of Therapy Clinic at St. Jude and primary care for survivors of pediatric solid tumors. The annual ASCO Meeting is typically quite busy and full of research presentations sharing knowledge and advances in cancer treatment and care. Today, I'd like to highlight some of the exciting presentations in pediatric cancer. Please note, I do not have any relationships to disclose related to any of these studies. At this year's meeting, one of the highlights was a European study in patients with relapsed or refractory Ewing sarcoma. Ewing sarcoma is a rare bone cancer that typically occurs in adolescents or young adults. While challenging to treat, it is difficult to cure in patients who have relapsed, and studies are needed to improve the care of these patients. Investigators from 13 European countries and Australia and New Zealand studied the most common relapsed therapies, which include irinotecan and temozolomide, gemcitabine and docetaxel, topotecan and cyclophosphamide, or high-dose ifosfamide. The study enrolled 451 patients between 2014 and 2021 and randomly assigned them to one of these four treatments. Based on response rates, the first 2 arms were dropped and the study was largely a comparison between topotecan cyclophosphamide and high-dose ifosfamide. The main outcome was event-free survival. Event-free survival is a common way in a clinical trial to see how well a treatment works. It measures the time from treatment that the patient remains free of complications, such as return or progression of the cancer. But investigators also looked at overall survival, toxicity, and quality of life. The 6-month event-free survival was better for high-dose ifosfamide at 47% compared to 37% for topotecan cyclophosphamide. The median overall survival was also better for high-dose ifosfamide compared to topotecan cyclophosphamide. The results were best for children younger than 14 years old versus those 14 or greater. Toxicities included fever and neutropenia, nausea, vomiting, and diarrhea. Patients receiving high-dose ifosfamide had more neurologic and kidney toxicities, which might be expected since ifosfamide is known to affect these organ systems, while only descriptive measurements of quality of life appeared higher for those children treated with high-dose ifosfamide compared to topotecan and cyclophosphamide. The strength of this trial is its large size, particularly for a rare cancer, and the fact that it randomized patients to the most commonly used treatment regimens for relapsed Ewing sarcoma. Importantly, data did not previously exist comparing these different treatments. While the results of this study are promising, clearly more needs to be done, and there was a lot of discussion at the ASCO Meeting about how to further improve survival in these patients. This study provides some information for doctors and patients, but importantly, provides data to advance future trials, which will concentrate on incorporating new targeted drugs with high-dose ifosfamide. This study is ongoing and is adding additional arms to continue to improve the outcomes for patients with relapsed or refractory Ewing sarcoma. In addition to this study in Ewing sarcoma, several studies investigating neuroblastoma were presented. Neuroblastoma is the most common extracranial solid tumor in children and for children with high-risk disease requires intensive and prolonged treatment, including chemotherapy, surgery, radiation therapy, and stem cell transplantation. Treatment for these patients has improved since the introduction of immunotherapy, particularly an antibody directed at a particular antigen named GD2 on the neuroblastoma cells. One study showed improvement in outcomes using this antibody for children with relapsed or refractory neuroblastoma, and another study demonstrated feasibility of using this antibody earlier in treatment, which was not previously known to be safe and tolerable. In what is called the BEACON study, investigators tested whether the antibody, called dinutuximab, would be effective when combined with chemotherapy for relapsed or refractory neuroblastoma. They enrolled 65 patients from 2019 to 2021 and randomized these patients to either chemotherapy alone or chemotherapy plus dinutuximab. The median age of these children was 4 years. The overall response rate, which means either a complete or partial response, was 18% for the chemotherapy-only arm but improved to nearly 35% for those treated with chemotherapy and dinutuximab. The progression-free survival was 27% for chemotherapy only and improved to 57% for those treated with chemotherapy and the antibody. There was no change in overall survival, though investigators think this may have been due to some patients who had progressive disease and crossed over to the antibody arm of the study. This presentation was followed by a study from the Children's Oncology Group, which investigated the feasibility of adding antibody treatment earlier in the treatment regimen for neuroblastoma. Prior studies had used antibody later in treatment when the tumor burden is thought to be lower. The endpoint of this study was tolerability measured by toxic deaths or unacceptable toxicities, such as adverse reactions to the medication. For example, sustained low blood pressure requiring a ventilator or breathing machine, or severe neuropathy. 42 high-risk neuroblastoma patients were enrolled from 8 different children's hospitals between 2019 and 2021. 41 of the 42 were able to complete the induction chemotherapy plus the antibody. There were no toxic deaths or unacceptable toxicities. Importantly, 85% were able to complete the next phase of treatment, called the consolidation phase, and 79% were able to complete the following phase after consolidation, called post-consolidation. One-year event-free survival was 83%, and 1-year overall survival was 95%. Now, it's important to know these are still early results, and the trial recently closed, and some of the patients have only completed therapy within the last year. Both of these studies add to the knowledge of chemoimmunotherapy for children with high-risk neuroblastoma. These studies provide a foundation for larger randomized trials that will further advance the care of these children. And finally, another study looked at race, ethnic, and socioeconomic disparities among children treated for high-risk neuroblastoma on Children's Oncology Group studies. There were no differences in event-free survival, but there were differences in overall survival based on ethnicity. The 5-year survival was lowest for Hispanic patients at 47%, 50% for non-Hispanic other ethnicities, which included Asian, Native American, Native Hawaiian, or Pacific Islanders, and 62% for non-Hispanic Black and non-Hispanic White children. Importantly, these investigators also studied household and neighborhood poverty. Overall, survival was lower for children living in poverty, though some of these differences went away when accounting for other factors, such as stage of disease or high-risk features. This study is important because it highlights the increasing need to collect data on clinical trials that may contribute to inequities in outcomes. While most studies collect data on the race and ethnicity of participants, other factors known as social determinants of health, such as income, neighborhood, education, access to health care, and insurance coverage, may also contribute to outcomes in pediatric cancer patients. Overall, the studies highlighted here and presented at this year's ASCO Annual Meeting focused on difficult-to-treat cancers, such as relapse or refractory disease, and they have laid the groundwork for future investigations to continue to improve survival rates for all children diagnosed with a malignancy through improved therapies and by addressing potential social barriers. Thank you for listening to this brief summary of the new research in pediatric oncology presented at the 2022 ASCO Annual Meeting. ASCO: Thank you, Dr. Mulrooney. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

NBL Podcasts
The Huddle: CJ Bruton - Making Adelaide Great Again

NBL Podcasts

Play Episode Listen Later Sep 13, 2022 24:27


36ers Head Coach, CJ Bruton, talks facing the pressure after his side's big Free Agency splash, buying into a winning culture and what success looks like for Adelaide this season.

Sports Show with Rowey & Bicks
INTERVIEW: CJ Bruton - 7 September 2022

Sports Show with Rowey & Bicks

Play Episode Listen Later Sep 7, 2022 4:49


See omnystudio.com/listener for privacy information.

Keeping Current CME
Are We Ready for More BTK Inhibitors in Chronic Lymphoblastic Leukemia? Experts Discuss the Latest Data

Keeping Current CME

Play Episode Listen Later Aug 25, 2022 32:10


Did you know that noncovalent Bruton tyrosine kinase (BTK) inhibitors are a potential solution to overcome the challenge of covalent BTK inhibitor resistance in chronic lymphoblastic leukemia (CLL)? Credit available for this activity expires: 8/24/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/979645?src=mkm_podcast_addon_979645

Morning Mayhem
Hog Song- Hogs Above or Below the Knee by Briggs Bruton

Morning Mayhem

Play Episode Listen Later Aug 23, 2022 1:51


Submit yours by Friday (8/26) to rj@1037thebuzz.com

Big Al & JoJo
08-09-22 David Bruton Jr with the Sports Zoo

Big Al & JoJo

Play Episode Listen Later Aug 9, 2022 17:18


Broncos Country Tonight
08-08-22 SB 50 Champ David Bruton Jr with Ryan and Ben

Broncos Country Tonight

Play Episode Listen Later Aug 9, 2022 9:11


David Bruton Jr. joined the show to discuss down roster players doing what it takes to make the team, his thoughts on Justin Simmons and Kareem Jackson, and preview his inaugural Bruton's Books golf event at Green Valley Ranch Golf Club on August 29th.

The Contracting Handbook
Jake Bruton of Aarow Building: Act like a real company!

The Contracting Handbook

Play Episode Listen Later Aug 8, 2022 63:07


The Contracting Handbook podcast is all about the builders and skilled tradesmen and tradeswomen in the construction industry from all over the world. Here you'll meet the tradespeople who took a leap of faith from working their craft to running the own construction company. You'll meet people who left lucrative careers to enter the trades. For newcomers to running a construction business, there is a ton of advice on “how to” run your contracting company. For established contractors, you get to meet other industry leaders and get behind the scenes of their business and stay up to date with industry change. Mike Knoche, your host, keeps the conversation interesting. He's been operating his contracting business for over 15 years in the oddly wonderful, Fairbanks, Alaska. Mike's philosophy is “we are all experts in how we build where we live, but the business basics and business management are universal”. Join us for this global conversation on operating a construction company, mental health, cool projects, and construction industry progress. Host: Mike KnocheWebsite: The Contracting HandbookInstagram: @thecontractinghandbookVenmo: Mike-Knoche-1info@thecontractinghandbook.com Guest: Jake BrutonInstagram: @jake.bruton

Riding The Pine
Ep. 237 Former Minor League Baseball Player Tyler Smith, Former Overseas Pro Basketball Player Case Bruton

Riding The Pine

Play Episode Listen Later Aug 2, 2022 49:26


Join me for another brand new episode of Riding The Pine! On today's new episode, I'm joined by not just one but two fantastic guests who share their transition out of professional sports, former minor league baseball player Tyler Smith (1:58-31:55) and former overseas pro basketball player Case Bruton (31:58-48:21)! Tyler and Case share an update into what life has been without playing professional sports, what the biggest adjustment was for each of them not having to worry about practice or games, takeaways from pro sports that they apply in their current careers and so much more! Intro: 0:00-1:57Interview w/ Tyler Smith: 1:58-31:55Interview w/ Case Bruton: 31:58-48:21Outro: 48:22-49:26

The Past Lives Podcast
Paranormal Stories Ep21

The Past Lives Podcast

Play Episode Listen Later Jul 7, 2022 22:26 Very Popular


Episode 21 of Paranormal Stories. This week the books are 'The In Between: A Trip of a Lifetime' by Jim Bruton and 'The Believer: Alien Encounters, Hard Science and The Passion of John Mack' by Ralph Blumenthal.Jim Bruton, 'The In Between: A Trip of a Lifetime'. Built airplane. Flew airplane. Crashed airplane. Met God. all set.Jim Bruton knows life. His past is marked by relentless curiosity and remarkable achievement. He was an African wilderness guide, Emmy Award-winning wildlife film director, aviator, adventurer, inventor of the satellite videophone, NBC News Middle East war correspondent, a husband, and a father.His passion - building and flying WWI-era aircraft - led him where he never imagined he'd go: a horrific crash that left him for dead. For one week, Jim Bruton hovered in the place that is not life and not death, a place he came to know as the In Between. He came back, and this is his report of what he has seen.Bruton takes us along for a by turns hair-raising and ultimately triumphant story of his coming to grips with what has happened to him. As he heals, his experiences in the In Between become more and more pressing. They download into his mind like rushing movie stills. His life of action turns internal. He uses all he knows - from quantum physics and battlefield memories to scenes of childhood and familial love - for a new deeper understanding of what it means to live.Jim Bruton, the man who fell from the sky, is not the same man who flew into it. And if you walk some of his journey with him, neither are you.About the author: Jim Bruton has lived a life many people dream of but few experience. As a little boy, he lived within an active imagination, including a love for wildlife filming, international travel, science fiction, and vintage aviation. In adulthood, he checked every one of those off his list with internationally recognized achievements, an Emmy for a National Geographic wildlife film, traveling to all seven continents, the Titanic, the North Pole, and Mt. Everest, shrinking a satellite TV truck into a backpack, and transmitting live video from places before impossible and building and flying historical reproduction aircraft from World War I and the early 1930s.For many, any one of these adventures resulted in a single lifetime achievement. For Jim, it was just the beginning, climaxing with the crash of his last aircraft and the near-death experience that followed.Jim is an Emmy award winning journalist and in this episode we talk about his about his Near Death Experience.From Jim's website;Generally, people who have had NDEs aren't trying to “sell” anything, other than perhaps a seminar, book or DVD. We don't try to sell a new religion, because we left all that behind. However, spirituality plays a pretty strong role in the experiences we share. One of the strangest things I've noticed is that for those of us who had our NDEs as a result of some horrific accident, while in most cases the accident and its crazy circumstances would be the focus of any compelling story, an NDE negates that. Once an NDE enters the picture, you almost forget about the accident- it becomes the least important part of the story, next to the NDE. My accident was amazing as accidents go, and I have an NDE friend who is only one of a handful in the world that she knows of who suffered and survived an internal decapitation. But to NDE'ers, the circumstances that nearly, or do, kill us are just a footnote. I'm sure that must be surprising, in some way.https://www.inbetweenproductions.com/https://www.amazon.com/Between-Trip-Lifetime-Jim-Bruton-ebook/dp/B098KQHX57/ref=tmm_kin_swatch_0?_encoding=UTF8&qid=1657203432&sr=8-1Ralph Blumenthal 'The Believer: Alien Encounters, Hard Science, and the Passion of John Mack'.The Believer is the weird and chilling true story of Dr. John Mack. This eminent Harvard psychiatrist and Pulitzer Prize–winning biographer risked his career to investigate the phenomenon of human encounters with aliens and to give credibility to the stupefying tales shared by people who were utterly convinced they had happened.Nothing in Mack's four decades of psychiatry had prepared him for the otherworldly accounts of a cross section of humanity including young children who reported being taken against their wills by alien beings. Over the course of his career his interest in alien abduction grew from curiosity to wonder, ultimately developing into a limitless, unwavering passion.Based on exclusive access to Mack's archives, journals, and psychiatric notes and interviews with his family and closest associates, The Believer reveals the life and work of a man who explored the deepest of scientific conundrums and further leads us to the hidden dimensions and alternate realities that captivated Mack until the end of his life.BioRalph Blumenthal, a Distinguished Lecturer at Baruch College of the City University of New York, was an award-winning reporter for The New York Times from 1964 to 2009, and has written seven books on organized crime and cultural history. He led the Times metro team that won the Pulitzer Prize for breaking news coverage of the 1993 truck-bombing of the World Trade Center. In 2001, Blumenthal was named a Fellow of the John Simon Guggenheim Memorial Foundation to research the progressive career and penal reforms of Warden Lewis E. Lawes, “the man who made Sing Sing sing.” The book on Warden Lawes, "Miracle at Sing Sing", was published by St. Martin's in June, 2004. His latest, "The Believer: Alien Encounters, Hard Science, and the Passion of John Mack," is coming out March 15, 2021 from High Road Books of the University of New Mexico Presshttps://www.amazon.com/Believer-Alien-Encounters-Science-Passion-ebook/dp/B08WWZFMMX/ref=tmm_kin_swatch_0?_encoding=UTF8&qid=1656670848&sr=8-1http://www.ralphblumenthal.com/https://twitter.com/ralphblu?lang=enhttps://www.pastliveshypnosis.co.uk/https://www.patreon.com/alienufopodcasthttps://www.patreon.com/pastlivespodcast

MarTech Podcast // Marketing + Technology = Business Growth
B2B Benefits of 24/7 Chat -- Nelson Bruton IV // Interchanges

MarTech Podcast // Marketing + Technology = Business Growth

Play Episode Listen Later Jun 26, 2022 15:31


In this second episode with Nelson, we talked about the benefits of having a human behind the chatbox 24/7 for B2B business and how it builds relationships during the early phase. We also discussed the costs associated in staffing and what's the process for dealing with site visitors who ask highly technical questions. Show NotesConnect With:Nelson Bruton: Website // LinkedIn The MarTech Podcast: Email // Newsletter // TwitterBenjamin Shapiro: Website // LinkedIn // TwitterSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

MarTech Podcast // Marketing + Technology = Business Growth
Two Decades of B2B Lead Gen Learnings -- Nelson Bruton IV // Interchanges

MarTech Podcast // Marketing + Technology = Business Growth

Play Episode Listen Later Jun 25, 2022 21:00


In our first episode with Nelson, we talked about the early challenges of digital marketing and how social media changed the whole dynamic of B2B partnership programs. We also discussed what the next evolution of B2B marketing is, are the fundamentals still the same, and why the software alone isn't the only solution for higher ROI. Show NotesConnect With:Nelson Bruton: Website // LinkedIn The MarTech Podcast: Email // Newsletter // TwitterBenjamin Shapiro: Website // LinkedIn // TwitterSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.